Notes
The study was funded by Boehringer Ingelheim (China).
Reference
Dong SJ, et al. Cost-effectiveness of dabigatran compared with rivaroxaban for prevention of stroke and systemic embolism in patients with atrial fibrillation in China. Clinical Therapeutics : 10 Jan 2020. Available from: URL: http://doi.org/10.1016/j.clinthera.2019.11.011
Rights and permissions
About this article
Cite this article
Dabigatran cost effective for stroke prevention in AF in China. PharmacoEcon Outcomes News 846, 11 (2020). https://doi.org/10.1007/s40274-020-6550-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6550-x